Advertisement


Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Peter Clark, MA, MD, FRCP: A Payer Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Advertisement